VAM
ONC

Visium Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Visium Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-99,670
Closed -$2.92M – 510
2016
Q1 		$2.92M Buy
+99,670
New +$2.82M 0.05% 347

Other funds holding ONC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Visium Asset Management's ONC Position: Q2 2016 in Review

Visium Asset Management sold out of BeOne Medicines Ltd (ONC) in Q2 2016, closing a stake of 99,670 shares — an estimated $2.92M sold.

Visium Asset Management first reported a position in ONC in Q1 2016 and held it in 1 quarter. The position peaked at $2.92M in Q1 2016. 39 funds tracked by Wall St. Rank hold ONC as of Q2 2016.

  • Visium Asset Management reported no remaining BeOne Medicines Ltd position as of Q2 2016 after selling out during the quarter.
  • Visium Asset Management sold 99,670 BeOne Medicines Ltd shares in Q2 2016, an estimated $2.92M.
  • Visium Asset Management first reported a position in BeOne Medicines Ltd in Q1 2016 and held it in 1 quarter.
  • Visium Asset Management's BeOne Medicines Ltd position peaked at $2.92M in Q1 2016.
  • 39 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.